Letters by information on its negative predictive value would enable the requesting clinician to decide whether to proceed to small bowel biopsy.
In contrast, the relatively poor specificity of IgA anti-gliadin antibodies, ranging from 65-100%3 (irrespective of assay method), generates a large number of false positives in this setting. Indeed, we are aware of at least one regional centre which has recently abandoned the use of antigliadin antibodies as a diagnostic marker for coeliac disease.
While the identification of tissue transglutaminase (TT) as the autoantigen in coeliac disease" has raised hopes of further improvements in diagnostic testing, in practice unpublished work (0 J Unsworth, personal communication) has demonstrated that antibodies to TT are no better than anti-endomysial antibodies as a diagnostic marker.
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Clinical application of intact parathyroid hormone assays
In their review of the clinical application of serum parathyroid hormone (PTH) assays, Ashby et al,' mention the association between serum PTH ranges and the types of bone disease found in renal patients receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPO). They also refer to the range of serum PTH concentrations (1,5-2'5 times the upper limit of normal) that should be achieved for adequate control of secondary hyperparathyr- Values less than 50 pg/rnl, (ng/L) suggest the presence of adynamic bone disease. In children with renal disease treated by haemodialysis, serum PTH concentrations should be kept below twice the upper limit of the (normocalcaemic) reference range. As reviewed, the accurate diagnosis of adynamic bone disease in chronic renal failure patients who are receiving haemodialysis, by means of serum bone markers, is not possible. A spate of recent publications have given sensitivity and specificity data for analytes such as PTH,4.5 osteocalcin'':" and bone alkaline phosphatase isoenzyme.v" all possessing insufficiently high positive predictive indices to act as useful diagnostic tools. However, Gerakis et al. 4 found that serum PTH had a negative predictive value for adynamic bone disease of greater than 90'1'0.
Ashby et al,' also mention in their section on hypoparathyroidism that serum PTH concentration should be "inappropriately low" in relation to the prevailing serum calcium concentration. Is it time that these subjective assessments are replaced by a more objective approach to diagnosis of hypoparathyroidism? Dynamic function tests have been shown to improve the sensitivity of detection (in a selected group of patients) of intact PTH for hypoparathyroidism." The selected upper limit of serum intact PTH [Nichols Allegro kit (Nichols Institute Diagnostics Ltd, Saffron Walden, UK)] was 51 ng/L, At this level the differential diagnosis should include familial hypocalcaemia, and Heath? advises the inclusion of family screening studies in the investigations.
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Blanking-out effects of haemolysis on Boehringer Mannheim creatine kinase (total and MB isoenzyme) assays
The Boehringer Mannheim (Mannheim, Germany) assays for total and MB creatine kinases
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(CK and CK-MB) are in widespread use because they are available on a main routine analyser and as such can be offered with relative ease for the investigation of acute myocardial infarction.
It is widely appreciated that this CK-MB immunoinhibition assay is subject to positive interferences by CK-BB (CK-3), macro CK and mitochondrial CK forms, but it is apparently less well appreciated that haemolysis can also affect results. The effect is due to the presence of residual adenylate kinase activity, because the added inhibitors diadenosine pentaphosphate and adenosine pentaphosphate are not able to inhibit adenylate kinase completely. Interference by haemolysis is a serious drawback and one that is correctable by using a rate B assay application which blanks out residual adenylate kinase activity prior to adding the substrate creatine phosphate (Fig. I) .
My laboratory has been using the rate B assay (serum-blanked) application for these tests for the past 10 years, first on Hitachi 705 and now on Hitachi 717 instrumentation (Hitachi Ltd, Tokyo, Japan). It is disappointing to me that the vendor of this instrumentation has chosen not to incorporate blanking for haemolysis into their assay applications for CK and CK-MB. The ability of individual users to implement such enhancements in their test applications is becoming more and more restricted. For example, the Hitachi 917 is limited to only five extra channels that permit user modifications. Laboratories must therefore rely on suppliers to include test applications that overcome known analytical interferences. Users should not be 100 
